Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Amgen (AMGN) is a biotech company based in California. It specializes in developing treatments for cardiovascular conditions, ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Eli Lilly has stepped up its campaign to encourage people to use its weight-loss drug Zepbound over copycat drugs from other sources, such as compounding pharmacies. The drugmaker used a 30-second ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...

A view shows MMR vaccine at the City of Lubbock Health Department in Lubbock, Texas, U.S. February 27, 2025. Texas and New Mexico on Tuesday reported an increase of 28 cases of measles in the last ...